Drug intelligence / Profile preview

SVF Vaccines HIV vaccine

Development stage: Preclinical
Lead developer: SVF Vaccines
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

SVF Vaccines HIV vaccine is an experimental vaccine candidate currently in preclinical development for the prevention or treatment of Human Immunodeficiency Virus (HIV) infection. Developed by SVF Vaccines, the candidate utilizes a nucleic acid-based platform that can be configured as either a DNA or mRNA vaccine. The technology is designed to deliver genetic instructions to host cells, prompting the production of viral antigens that trigger a robust immune response against HIV. As of early 2026, the program remains in the discovery and preclinical stages of development.

Other names: HIV vaccineSVF HIV vaccine

Beyond the preview

Go deeper on SVF Vaccines HIV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVF Vaccines HIV vaccine.

Explore the full profile